NEW YORK (GenomeWeb News) – Informatics company Genstruct said today it will collaborate with Pfizer on current and future preclinical drug safety studies.
Under a new master research agreement, Genstruct will initially work with Pfizer on a systems biology analysis of the biological mechanisms that underlie drug-induced liver injury.
Genstruct President and CEO Keith Elliston said the company has previously worked with Pfizer on oncology, vascular injury, cardiovascular, and metabolic disease.
Genstruct focuses on integrating and analyzing large-scale data from transcriptomic, proteomic, metabolomic, and phosphoproteomic research, Elliston said. The firm also applies its technologies to finding biomarkers of efficacy and toxicity of drugs.
Financial terms of the agreement were not released, but Genstruct said that it retains biomarker intellectual property rights.